|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.395 HKD | 0.00% |
|
+8.22% | -14.13% |
| 03:17pm | Mabpharm's New Drug Application Gets Peru's Regulator's Approval | MT |
| 06-26 | Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA | CI |
Mabpharm Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 55.92 million compared to CNY 82.88 million a year ago. Net loss was CNY 210.82 million compared to CNY 291.74 million a year ago.
Basic loss per share from continuing operations was CNY 0.05 compared to CNY 0.07 a year ago. Diluted loss per share from continuing operations was CNY 0.05 compared to CNY 0.07 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -14.13% | 209M | |
| +17.15% | 122B | |
| +18.36% | 114B | |
| +19.62% | 25.71B | |
| -25.44% | 19.02B | |
| -20.21% | 15.83B | |
| -19.49% | 15.32B | |
| -47.37% | 14.88B | |
| +61.81% | 14.82B | |
| +5.21% | 14.1B |
MABPHARM LIMITED 
